AstraZeneca PLC (AZN)vsMaxCyte Inc (MXCT)
AZN
AstraZeneca PLC
$183.02
+1.10%
HEALTHCARE · Cap: $284.30B
MXCT
MaxCyte Inc
$1.19
+2.50%
HEALTHCARE · Cap: $129.62M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 187093% more annual revenue ($60.44B vs $32.29M). AZN leads profitability with a 17.2% profit margin vs -121.2%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
MXCT
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+5.9%
Fair Value
$194.57
Current Price
$183.02
$11.55 discount
Intrinsic value data unavailable for MXCT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : MXCT
The strongest argument for MXCT centers on Price/Book, Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : MXCT
The primary concerns for MXCT are EPS Growth, Altman Z-Score, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while MXCT is a turnaround play — different risk/reward profiles.
MXCT carries more volatility with a beta of 1.67 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 28/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
MaxCyte Inc
HEALTHCARE · MEDICAL DEVICES · USA
MaxCyte Inc. (MXCT) is a leader in cell-engineering, renowned for its innovative Flow Electroporation® technology that enables efficient and scalable delivery of nucleic acids and proteins into a variety of cell types. The company serves a prestigious clientele, including top biopharmaceutical firms and research institutions, positioning it favorably within the rapidly expanding cell and gene therapy market. MaxCyte's advanced platforms play a crucial role in the development of novel cell-based therapies and vaccines, responding to the growing global demand for transformative healthcare solutions. With a steadfast commitment to enhancing patient outcomes, MaxCyte is poised to capitalize on significant market opportunities in the life sciences sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?